Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 686 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
5 Results
A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome
- Leukemia & Hematologic Cancers
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
- Leukemia & Hematologic Cancers
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes
- Leukemia & Hematologic Cancers
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
- Leukemia & Hematologic Cancers
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- Leukemia & Hematologic Cancers